Nonexudative Macular Neovascularization in Age-Related Macular Degeneration - Summary - MDSpire

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • By

  • Sridevi Thottarath

  • Sarega Gurudas

  • Syed Kubravi

  • Dimitrios Kazantzis

  • Ayse Merve Keskin

  • Sobha Sivaprasad

  • EYENEON Study Group

  • Benjamin Burton

  • Geeta Menon

  • Manju Chandran

  • Ian Pearce

  • Savita Madhusudhan

  • Anna Grabowska

  • Faruque Ghanchi

  • James Talks

  • Richard Gale

  • Martin McKibbin

  • Ajay Kotagiri

  • Niro Narendran

  • Afsar Jafree

  • Saad Younis

  • Claire Bailey

  • Priya Prakash

  • Christiana Dinah

  • Louise Downey

  • Andrew Lottery

  • Paritosh Shah

  • Romi Chhabra

  • Narendra Dhingra

  • Indra Dias

  • Mary Freeman

  • Daren Hanumunthadu

  • May 1, 2026

  • 0 min

Share

Objective:

To evaluate the prevalence of subclinical nonexudative macular neovascularization (neMNV) and double-layer sign (DLS) in fellow eyes of patients with unilateral new-onset exudative age-related macular degeneration (nAMD), highlighting the potential implications for monitoring and treatment.

Key Findings:
  • Prevalence of neMNV in fellow eyes ranged from 6.25% to 27.00%, indicating a significant risk factor for progression.
  • DLS is a potential surrogate for neMNV but has limitations in grading, necessitating cautious interpretation.
  • Thick DLS (>1000 μm) more likely to harbor neMNV compared to thin DLS, suggesting a need for careful monitoring.
Interpretation:

Subclinical neMNV is common in fellow eyes of patients with unilateral exudative nAMD, and while DLS may indicate risk, it is not a definitive marker, warranting further investigation.

Limitations:
  • Variability in DLS grading and interpretation may affect the reliability of findings.
  • Potential selection bias due to study design could limit generalizability.
Conclusion:

The study highlights the importance of monitoring for neMNV in fellow eyes of nAMD patients, although DLS as a surrogate marker requires cautious interpretation and further research.

Original Source(s)

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • by Sridevi Thottarath, Sarega Gurudas, Syed Kubravi, Dimitrios Kazantzis, Ayse Merve Keskin, Sobha Sivaprasad, EYENEON Study Group, Benjamin Burton, Geeta Menon, Manju Chandran, Ian Pearce, Savita Madhusudhan, Anna Grabowska, Faruque Ghanchi, James Talks, Richard Gale, Martin McKibbin, Ajay Kotagiri, Niro Narendran, Afsar Jafree, Saad Younis, Claire Bailey, Priya Prakash, Christiana Dinah, Louise Downey, Andrew Lottery, Paritosh Shah, Romi Chhabra, Narendra Dhingra, Indra Dias, Mary Freeman, Daren Hanumunthadu

  • May 1, 2026

Related Content

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

Inside the Aging Eye

A comprehensive new Elsevier publication brings global expertise together to unpack how aging drives ocular structure, function, and disease

  • April 28, 2026

  • 2 min
Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks